For the first quarter of fiscal 2027, Medtronic is expected to report consensus EPS of $1.38 on revenue of $8.54 billion, with the stock currently trading at $91.45 against an average analyst price target of $104.20.
Investors are primarily focused on growth within the Diabetes segment, specifically the domestic and international adoption rates of the MiniMed 780G system and the new Simplera Sync sensor.
Supporting this focus, analysts are monitoring the performance of the Cardiovascular portfolio following the full-scale rollout of the PulseSelect PFA system. Management's commentary regarding margin expansion initiatives and the status of the patient monitoring spinoff will also be key drivers of post-earnings sentiment.